CALGENE PRESIDENT RESIGNSZachary Wochok has resigned as president and chief executiveofficer of Calgene Inc. (NASDAQ:CGNE), an agbiotech company inDavis, Calif. Wochok, president of Plant Genetics Inc. when itwas acquired by Calgene in 1989, plans to become anindependent biotechnology consultant. Calgene said nosuccessor will be named and that Wochok's duties will beshared by Andrew Baum, senior vice president of operations,and Daniel Wagster, chief financial officer.
Elliott D. Hillback Jr. has become president and chief executiveofficer of Integrated Genetics Laboratories (NASDAQ:IGLI), aFramingham, Mass., developer and marketer of genetic testingservices. Hillback, who had been senior vice president ofGenzyme Corp. as well as a member of IG Lab's board ofdirectors since 1991, replaces Peter Lanciano, who resigned topursue other business interests.
Gerald D. Laubach, former president and chief executive officerof Pfizer Inc., has joined the board of DNA Plant TechnologyCorp. (NASDAQ: DNAP) of Cinnaminson, N.J. With Laubach, theboard now has 10 directors.
Jack Vaughn and Michael Viguerie have been named to the boardat Imre Corp. (NASDAQ:IMRE), a Seattle developer and producerof technology for treating blood outside the body. Vaughn is asenior regional adviser in Central America for the Agency forInternational Development. Viguerie is formerly a generalmanager for American Hospital Supply Corp. Jack Halperin hasresigned from the board of directors for personal reasons, thecompany said.
Rina K. Spence has been elected to the board of TSI Corp.(NASDAQ:TSIN), a Worcester, Mass., developer of toxicologytests and pharmaceutical proteins. Spence is president andchief executive officer of Emerson Hospital and EmersonHealth Systems Inc.
Roland Greenberg, formerly director of clinical pharmacologyat Bristol-Myers Squibb Co., has joined Glycomed Inc.(NASDAQ:GLYC) as director of corporate development. Wendy K.Swenson, formerly associate director of biologicaltherapeutics development for Cetus Corp., has joined theAlameda, Calif.-based Glycomed, which develops complexcarbohydrates, as director of project management.
Peter V. Pallai, Ph.D., has been named director of rational drugdesign at Procept Inc., a Cambridge, Mass., developer oftherapeutic compounds. Pallai is former section head in theDepartment of Medicinal Chemistry at Boehringer IngelheimPharmaceuticals.
Exogene, a Monrovia, Calif., company developing oxygen-enhancing technologies that improve productivity in processesfor a wide range of products, named James David Rozzell, Ph.D.,vice president of research and development. Rozzell wasdirector of industrial chemical R&D and bioremediation atCelgene Corp.
James W. Kelly, chief executive officer at Crop GeneticsInternational Corp. (NASDAQ:CROP) has been named to theadditional post of chairman of the agricultural biotechnologycompany. Kelly succeeds John B. Henry, who left to form asimilar company, a Crop Genetics spokeswoman said.
Patricia H. McPherson has become East Coast director ofclinical research for the Institute for Biological Research andDevelopment Inc., an Irvine, Calif., provider of pharmaceuticaland biomedical product research. McPherson, who will helpexpand IBRD's East Coast operations, is the former manager ofthe Riverview Clinical Studies Center at VRG International.
Medicis Pharmaceutical Corp. (NASDAQ:MDRXA, MDRXU), a NewYork marketer of dermatalogical products, has named RobertMetz director of consumer sales and Lisa Cashavelly marketingmanager of its Consumer Brands division. Metz is formermanager of retail operations at Shulton Inc. and Cashavellywas previously a product manager at Bristol-Myers Squibb Co.
Ellen Molleston Walvoord has been named vice president ofinvestor relations and public affairs of Abbott Laboratories(NYSE:ABT), an Abbott Park, Ill., manufacturer of health careproducts. Molleston, formerly vice president of investorrelations, replaces Richard B. Hamilton, who resigned forpersonal reasons.
(c) 1997 American Health Consultants. All rights reserved.